Stock Focus. Pioneer Credit (PNC) Tuesday, 12 April 2016

Size: px
Start display at page:

Download "Stock Focus. Pioneer Credit (PNC) Tuesday, 12 April 2016"

Transcription

1 Stock Focus Pioneer Credit (PNC) Tuesday, 12 April $2.03 $2.48 $1.69 Share Price $2.82 Positive Neutral Negative Trading Data Last Price $ month range $ $1.85 Market Cap $78m Free Float $48m (62%) 12 month return (historical) 2.8% <insert text here> WHAT SURPRISED? PNC has raised $5.8m in new equity at $1.70 per share (last sale 11 April 2016 $1.695). The funds will be used to accelerate the Company s growth through the acquisition of further parcels of consumer debt. In recent updates PNC has indicated that the PDL purchasing environment is changing, with the intensity of competition waning. This follows a period of higher prices being paid for debt parcels. For the most part this has been an issue for PNC s competitor base, with the Company remaining disciplined with its investment process. Importantly PNC maintains its purchasing guidance of at least $42m in FY16. As such the capital raising supports growth in FY17. This is consistent with previous communications by the company that it expects solid growth in purchases, at appropriate price points, through FY17. EAP forecasts FY17 purchases of $49m, an increase of 17% on FY16. PNC has also reiterated FY16 NPAT guidance of at least $8.8m. WHAT'S CHANGED? Incorporating the share placement our FY16E and FY17 EPS declines 2% and 4% respectively. Despite the purpose of the raising we leave our PDL purchase forecast of $49m for FY17 unchanged at this stage. Valuation remains unchanged at $2.26, with increases in relative multiples since last publication offsetting the dilution of the share placement. WHAT NOW? PNC remains our top pick among the receivables management companies. Importantly the Group differs from its industry peers with an approach premised on understanding its customers circumstances rather than aggressively pursuing collections. As a result the Company typically receives payment over a longer period of time 6-10yrs. However the pay-off is improved recoveries of around 3x PDL investment. In addition, the Company s investment process concentrates on bank related debt and avoids many of the lower quality debt parcels such as account billings (telcos & utilities). As a relatively smaller but growing player, PNC can also benefit from smaller purchases and afford to be more selective in its investment process. With the above in mind we maintain our Positive rating on PNC. <insert text here> Earnings Forecasts Yr to June 13A 14A 15A 16E 17E 18E EBITDA ($m) Rep NPAT ($m) Adj NPAT ($m) EPS ( ) EPS Gth (%) NM NM PER (x) PEG Ratio (x) DPS ( ) Yield (%) Franking (%) ROE (%) 1 15% 14% 16% 18% EV/EBITDA (x) Net Debt/EBITDA (x) Int. Cover (x) (10.8) (8.8) (14.8) (6.1) (5.9) (5.6) Valuation (blended) $2.26 Source: EAP Research PAGE 1 OF 5

2 PNC BALANCE SHEET CAPACITY The business of PDL investment and receivables management is a capital intensive business. Purchases must be made upfront, with the recovery of outstanding principal typically received over the course of next six-ten years. In addition, growth requires every increasing purchases. While we remain comfortable with PNC s debt servicing capacity, there are some limitations to growth with Net Debt/Debt + Equity at around 47% in FY17E. This is based on EAP s forecasts for $49m in PDL purchases for FY17. While we don t forecast revaluations of the PDL portfolio, PNC could also benefit from an upwards revaluation which would also allow for additional headroom. This is a unique and less visible element of the Group s valuation process given PNC adopts a fair value approach to its PDL valuations. In the last two years the Group has benefitted from upwards revaluations which have been carried through the profit and loss. Importantly EBIT interest cover is reasonable at 4.9x FY17E (EAP s forecasts). In short investors should not discount the prospect of future capital raisings, depending on PNC s growth in PDL purchases. Indeed, capital management is a natural function of any growth company in a capital intensive industry. PNC s Forecast PDL Purchases & Gearing Post Placement Source: Company Data, EAP Research PNC s Net DEBT:PDL Value Source: Company Data, EAP Research Forecast PDL Purchases Net Debt / Net Debt + Equity RHS Carrying Value of PDL Net Debt / PDL Value Bank Covenant Net Debt to PDL Value 55% E 2017E 2018E E 2017E 2018E EARNINGS & VALUATION While we have faith that PNC will put the $5.8m raised to work, we have not altered our FY17 purchasing forecasts of $49m. Incorporating the share placement our FY16 and FY17 EPS decline 2% and 4% respectively. Due to change in relative multiples since last publication our valuation remains unchanged at $2.26. EARNINGS REVISIONS Metric Revenue ($m) EBIT ($m) EPS pre Amort'n ( ) DPS ( ) Yr to June Old New % Chg Old New % Chg Old New % Chg Old New % Chg 2016E (2%) E (4%) (5%) 2018E (5%) (7%) Blended Valuation $2.26 $2.26 () Source: Company data, Evans & Partners Research estimates PAGE 2 OF 5

3 FINANCIAL SUMMARY Pioneer Credit PNC As at: 12/04/2016 Recommendation: Positive Share Price $1.70 Year end June 2015A 2016E 2017E 2018E INCOME STATEMENT Sales Revenue $m Consolidated EBITDA $m D&A $m Consolidated EBIT $m Net Interest $m Tax Expense $m Associates/Minorities $m Adj NPAT $m NRIs $m Reported NPAT $m Shares on Issue (end period) m EFPOWA m EPS DPS Franking % GROWTH/PROFITABILITY RATIOS Sales Growth % % 21.1% 18. EBITDA Growth % 62.9% 29.2% % EBIT Growth % 58.6% 29.9% 20.6% 28.6% EPS Growth % 70.4% 12.1% 12.7% 27.3% EBITDA/Sales % 33.3% 35.3% 35.3% 38.2% EBIT/Sales % 30.9% 32.9% 32.8% 35.7% EBIT Interest Cover x (14.8) (6.1) (5.9) (5.6) Tax Rate % 29.5% ROE % 14.8% 14.3% 15.7% 18.1% ROFE % 14.2% 14.2% 14.3% 15.8% CASH FLOW EBITDA $m Change in Working Capital $m (7) Other $m Gross Operating Cash Flow $m Net Interest Paid $m (1) (3) (3) (4) Tax Paid $m (3) (4) (5) (6) Net Operating Cash Flow $m Maintenance Capex $m (1) (1) (1) (1) Free Cash Flow $m Dividends Paid $m (2) (4) (5) (6) Expansionary Capex $m (43) (45) (49) (54) Acquisitions $m Asset Sales $m Dividends Received $m Shares Issues/Buybacks $m Other $m Increase in Net Cash/(Debt) $m (27) (15) (16) (14) GOCF/EBITDA % 76% 101% 101% 101% Total Capex/Sales % 113.4% 98.4% 88.9% 82.9% Total Capex/Depreciation x (46.6) (41.2) (35.5) (33.2) Source: Company data, E&P Research estimates Year end June 2015A 2016E 2017E 2018E VALUATION METRICS PER x P/EG (2YR) x Dividend Yield % % 6.2% 7.6% EV/EBITDA x EV/EBIT x P/FCF x P/BV x BALANCE SHEET Assets Cash $m Working Capital $m PP&E $m Intangibles $m Investments $m Other $m Total Assets $m Liabilities Debt $m Working Capital $m Other $m Total Liabilities $m Equity $m Capital Employed $m Net Debt/(Cash) $m Net Debt/Equity % 58% 72% 89% 99% Net Debt/Debt+Equity % 36.7% 41.8% 47.1% 49.6% Net Debt/EBITDA x Working Capital/Sales % 73% 106% 106% 105% D&A/PP&E % (21.7%) (27.7%) (38.6%) (51.5%) DCF VALUATION $m $/share Risk Free Rate 5.5% Enterprise Value 113 $2.28 Market Risk Premium 5.7% (Net Debt)/Cash (31) ($0.62) Beta 1.20 Franking Credits $0.39 WACC 9.2% DCF Valuation $2.05 Margin Trends 21% Return Trends Gearing & Interest Cover -4 38% 18% % 15% -8 34% 12% % 9% -12 6% % 3% -16 EBITDA/Sales EBIT/Sales ROE ROA ROFE - Reported Net Debt/Net Debt+Equity (%) EBIT Interest Cover (x) Source: Company data, E&P Research estimates PAGE 3 OF 5

4 Positive Neutral Negative Speculative Buy Suspended Not Rated Stock is expected to outperform the S&P/ASX 200 over the coming 24 months Stock expected to perform in line with the S&P/ASX 200 over the coming 24 months Stock is expected to underperform the S&P/ASX 200 over the coming 24 months Stock has limited history from which to derive a fundamental investment view or its prospects are highly dependent on event risk, eg. Successful exploration, scientific breakthrough, high commodity prices, regulatory change, etc. Stock is temporarily suspended due to compliance with applicable regulatory and/or Evans & Partners policies in circumstances where Evans & Partners is acting in an advisory capacity. Stock is not included in our investment research universe. Research Criteria Definitions Recommendations are primarily determined with reference to how a stock ranks relative to the S&P/ASX 200 on the following criteria: Valuation Earnings Outlook Earnings Momentum Shareholder Returns Debt Servicing Capacity Cyclical Risk Industry Quality Financial Transparency Rolling 12 month prospective multiples (composite of Price-to-Earnings Ratio, Dividend Yield and EV/EBITDA), or long-term NPV for resource stocks. Forecast 2 year EPS growth. Percentage change in the current consensus EPS estimate for the stock (rolling 1 year forward basis) over the consensus EPS estimate for the stock 3 months ago. Composite of forecast ROE (rolling 1 year forward basis) and the percentage change in ROE over 2 years. Rolling 12 month EBIT Interest Cover ratio. Qualitative assessment of the 2 year outlook for a stock/industry s profit cycle. Qualitative assessment of an industry s growth/returns potential and company specific management capability. If we don t understand it, we won t recommend it. For stocks where Evans & Partners does not generate its own forecasts, Bloomberg consensus data is used. Analysts can introduce other factors when determining their recommendation, with any material factors stated in the written research where appropriate. PAGE 4 OF 5

5 This document is provided by Evans and Partners ABN , holder of AFSL Please see our website at for important information regarding Evans and Partners research. The information is general advice only and does not take into consideration an investor s objectives, financial situation or needs. Before acting on the advice, investors should consider the appropriateness of the advice, having regard to the investor s objectives, financial situation and needs. If the advice relates to a financial product that is the subject of a Product Disclosure Statement (e.g. unlisted managed funds) investors should obtain the PDS and consider it before making any decision about whether to acquire the product. The material contained in this document is for information purposes only and does not constitute an offer, solicitation or recommendation with respect to the purchase or sale of securities. It should not be regarded by recipients as a substitute for the exercise of their own judgment. Investors should be aware that past performance is not an infallible indicator of future performance and future returns are not guaranteed. Any opinions and/or recommendations expressed in this material are subject to change without notice and Evans and Partners is not under any obligation to update or keep current the information contained herein. References made to third parties are based on information believed to be reliable but are not guaranteed as being accurate. This document is provided to the recipient only and is not to be distributed to third parties without the prior consent of Evans and Partners. Evans and Partners and its respective officers and associates may have an interest in the securities or derivatives of any entities referred to in this material. Evans and Partners does, and seeks to do, business with companies that are the subject of its research reports. Company AUI AYUHB BENPF CIE CGL DUI EAI IGL MGC MQGPB NAB SWM TGG TOX Nature of Relationship The Issuer has appointed Evans and Partners as Broker to an on-market buy-back. Accordingly, Evans and Partners is unable to give Sellers advice in respect to a sale of this security. Evans and Partners has been appointed as Placement Agent in respect of the company s renounceable rights issue and will receive fees for acting in this capacity. A director of Evans and Partners Pty Ltd is a director of The Citadel Group Limited. The Issuer has appointed Evans and Partners as Broker to an on-market buy-back. Accordingly, Evans and Partners is unable to give Sellers advice in respect to a sale of this security. Evans and Partners arranged, managed or co-managed a public offering of the company or its affiliates in the past 12 months A director of Evans and Partners Pty Ltd is a director of Seven West Media Limited. Evans and Partners Pty Ltd was appointed as Sponsoring Broker in relation to the 1 for 4 pro-rata entitlement offer (and any subsequent shortfall) of Templeton Global Growth Fund Limited (TGG) and will receive fees for acting in this capacity. Evans and Partners arranged, managed or co-managed a public offering of the company or its affiliates in the past 12 months I, Simon Fitzgerald, hereby certify that all the views expressed in this report accurately reflect my personal views about the subject investment theme and/or company securities. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. I, Simon Fitzgerald, and/or entities in which I have a pecuniary interest, have an exposure to the following securities and/or managed products: N/A Except for any liability which cannot be excluded, Evans & Partners, its directors, employees & agents accept no liability or responsibility whatsoever for any loss or damage of any kind, direct or indirect, arising out of the use of all or any part of this material. All information is correct at the time of publication; additional information may be available upon request. PAGE 5 OF 5

Result Focus. Pioneer Credit (PNC) Monday, 27 February 2017

Result Focus. Pioneer Credit (PNC) Monday, 27 February 2017 Result Focus Pioneer Credit (PNC) Monday, 27 February 2017. $2.25 $2.71 $1.94 Share Price $3.02 Positive Neutral Negative Trading Data Last Price $2.07 12 month range $1.60 - $2.09 Market Cap $101m Free

More information

Result Focus. Osprey Medical Inc. (OSP.ASX) Last price $0.38 Valuation $0.58. Thursday, 25 January 2018

Result Focus. Osprey Medical Inc. (OSP.ASX) Last price $0.38 Valuation $0.58. Thursday, 25 January 2018 Result Focus Osprey Medical Inc. (OSP.ASX) Thursday, 25 January 2018 Last price $0.38 Valuation $0.58 TSR Upside to valuation 51.8% Dividend yield 0.0% Expected total SH return 51.8% Trading Data Last

More information

Orbis Gold Ore Zone December 2014

Orbis Gold Ore Zone December 2014 . $0.32 $0.57 $0.89 Share Price $1.13 Positive Neutral Negative RECOMMENDATION: NEUTRAL (WAS SPECULATIVE BUY) Orbis was recently approached by Semafo with a proposed offer for the company of $A0.65. The

More information

Result Focus. Osprey Medical Inc. (OSP.ASX) Last price $0.15 Valuation $0.37. Tuesday, 30 October 2018

Result Focus. Osprey Medical Inc. (OSP.ASX) Last price $0.15 Valuation $0.37. Tuesday, 30 October 2018 Result Focus Osprey Medical Inc. (OSP.ASX) Tuesday, 30 October 2018 Last price $0.15 Valuation $0.37 TSR Upside to valuation 146.8% Dividend yield 0.0% Expected total SH return 146.8% Trading Data Last

More information

Boart Longyear. Earnings and target price revision. No change. Price catalyst. Action and recommendation

Boart Longyear. Earnings and target price revision. No change. Price catalyst. Action and recommendation AUSTRALIA BLY AU Price (at 08:01, 12 Sep 2013 GMT) Neutral A$0.50 Valuation A$ 0.71 - DCF (WACC 10.1%, beta 1.5, ERP 0.1%, RFR 0.1%, TGR 0.0%) 12-month target A$ 0.56 12-month TSR % +12.0 Volatility Index

More information

Silver Chef. Capital raising A$7.71 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation

Silver Chef. Capital raising A$7.71 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation AUSTRALIA SIV AU Price (at 08:50, 21 Mar 2017 GMT) Neutral A$7.71 Valuation - PER A$ 6.68 12-month target A$ 6.68 12-month TSR % -7.4 Volatility Index Medium GICS sector Capital Goods Market cap A$m 278

More information

SG Fleet Group. Another UK acquisition. Earnings and target price revision

SG Fleet Group. Another UK acquisition. Earnings and target price revision AUSTRALIA SGF AU Price (at 08:26, 30 Nov 2016 GMT) Outperform A$3.23 Valuation - PER A$ 3.96-4.22 12-month target A$ 4.37 12-month TSR % +41.0 Volatility Index High GICS sector Commercial & Professional

More information

BUY SHARE PRICE CASH EARNINGS ($M) COMPANY DATA & RATIOS

BUY SHARE PRICE CASH EARNINGS ($M) COMPANY DATA & RATIOS BUY 0.11 0.39 0.69 SHARE PRICE CASH EARNINGS ($M) COMPANY DATA & RATIOS CONTENTS Competitors Products Sales channels Pricing Model INVESTMENT THESIS COMPANY OVERVIEW INDUSTRY OVERVIEW COMPETITORS BOARD

More information

SG Fleet Group % growth in FY17. Earnings and target price revision. Price catalyst. Catalyst: Results and contract wins.

SG Fleet Group % growth in FY17. Earnings and target price revision. Price catalyst. Catalyst: Results and contract wins. AUSTRALIA SGF AU Price (at 07:57, 27 Oct 2016 GMT) Outperform A$3.85 Valuation - PER A$ 3.92-4.18 12-month target A$ 4.37 12-month TSR % +18.1 Volatility Index Medium GICS sector Commercial & Professional

More information

Eclipx Group. Highlights its funding flexibility A$3.77 AUSTRALIA. Event. Impact. Earnings and target price revision.

Eclipx Group. Highlights its funding flexibility A$3.77 AUSTRALIA. Event. Impact. Earnings and target price revision. AUSTRALIA ECX AU Price (at 02:49, 15 Dec 2016 GMT) Outperform A$3.77 Valuation - PER A$ 3.53-3.78 12-month target A$ 4.22 12-month TSR % +16.3 Volatility Index Low/Medium GICS sector Diversified Financials

More information

Platinum Asset Management

Platinum Asset Management AUSTRALIA PTM AU Price (at 06:10, 11 Jul 2016 GMT) Neutral A$5.52 Valuation A$ - DCF (WACC 9.3%, beta 1.2, ERP 5.0%, RFR 3.3%) 5.19 12-month target A$ 5.36 12-month TSR % +2.6 Volatility Index Low/Medium

More information

Vista Group International

Vista Group International NEW ZEALAND VGL NZ Price (at 03:15, 26 Feb 2015 GMT) Outperform NZ$4.35 Valuation NZ$ 4.31 - DCF (WACC 9.9%, beta 1.0, ERP 7.0%, RFR 4.0%, TGR 2.0%) 12-month target NZ$ 4.75 12-month TSR % +9.5 Volatility

More information

Cardno. Tough half over A$2.88 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation

Cardno. Tough half over A$2.88 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation AUSTRALIA CDD AU Price (at 04:53, 17 Feb 2015 GMT) Neutral A$2.88 Valuation - Sum of Parts A$ 2.80-3.43 12-month target A$ 3.12 12-month TSR % +18.4 Volatility Index Medium GICS sector Capital Goods Market

More information

Southern Cross Media. Streamlining ahead of reform? A$1.37 AUSTRALIA

Southern Cross Media. Streamlining ahead of reform? A$1.37 AUSTRALIA AUSTRALIA SXL AU Price (at 05:10, 27 Mar 2017 GMT) Neutral A$1.37 Valuation A$ - DCF (WACC 8.0%, beta 1.2, ERP 5.0%, RFR 3.3%) 1.39 12-month target A$ 1.30 12-month TSR % +0.8 Volatility Index Medium GICS

More information

Auckland International Airport

Auckland International Airport NEW ZEALAND AIA NZ Price (at 04:00, 27 Nov 2013 GMT) Neutral NZ$3.42 Valuation NZ$ 3.37 - DCF (WACC 8.0%, beta 0.9, ERP 7.0%, RFR 4.3%, TGR 3.0%) 12-month target NZ$ 3.37 12-month TSR % +2.6 Volatility

More information

Seek. Progresses Zhaopin privatisation A$16.33 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation

Seek. Progresses Zhaopin privatisation A$16.33 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation AUSTRALIA SEK AU Price (at 06:33, 07 Apr 2017 GMT) Outperform A$16.33 Valuation - Sum of Parts A$ 16.77 12-month target A$ 16.50 12-month TSR % +3.9 Volatility Index Low/Medium GICS sector Commercial &

More information

Fisher & Paykel Healthcare

Fisher & Paykel Healthcare NEW ZEALAND FPH NZ Price (at 05:00, 10 Jul 2015 GMT) Outperform NZ$7.03 Valuation NZ$ 7.39 - DCF (WACC 8.8%, beta 0.9, ERP 7.0%, RFR 4.5%, TGR 2.0%) 12-month target NZ$ 7.80 12-month TSR % +13.1 Volatility

More information

Tox Free Solutions. Winning work again A$2.34 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation

Tox Free Solutions. Winning work again A$2.34 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation AUSTRALIA TOX AU Price (at 05:10, 30 Nov 2016 GMT) Outperform A$2.34 Valuation - EV/EBITDA A$ 2.52-3.07 12-month target A$ 2.79 12-month TSR % +23.1 Volatility Index Medium GICS sector Commercial & Professional

More information

Orocobre. Upside exposure fading. Earnings and target price revision. Price catalyst. Catalyst: Update on projects or Q1 report

Orocobre. Upside exposure fading. Earnings and target price revision. Price catalyst. Catalyst: Update on projects or Q1 report AUSTRALIA ORE AU Price (at 5:11, 28 Feb 217 GMT) Neutral A$3.8 Valuation - DCF (WACC 1.%) A$ 1.34 12-month target A$ 3.17 12-month TSR % +2.9 Volatility Index High GICS sector Materials Market cap A$m

More information

IOOF. Positive flows in 1Q17. FUM and Net Flows for September Qtr Source: Company data, Macquarie Research, Oct 2016.

IOOF. Positive flows in 1Q17. FUM and Net Flows for September Qtr Source: Company data, Macquarie Research, Oct 2016. AUSTRALIA IFL AU Price (at 06:35, 26 Oct 2016 GMT) Outperform A$8.34 Valuation A$ - DCF (WACC 8.8%, beta 1.1, ERP 5.0%, RFR 3.3%) 8.74 12-month target A$ 9.00 12-month TSR % +14.3 Volatility Index Low/Medium

More information

UGL. Driving growth in DTZ. Earnings and target price revision. No change. Price catalyst. Action and recommendation

UGL. Driving growth in DTZ. Earnings and target price revision. No change. Price catalyst. Action and recommendation AUSTRALIA AU Price (at 08:17, 03 Sep 2012 GMT) Underperform A$10.52 Volatility index Low 12-month target A$ 11.08 12-month TSR % +12.0 Valuation A$ - DCF (beta 1.1, ERP 5.0%, RFR 6.0%, TGR 2.5%) 15.09

More information

Telstra Corporation. Vodafone better, but far from good A$6.43 AUSTRALIA. Event. Impact. Earnings and target price revision.

Telstra Corporation. Vodafone better, but far from good A$6.43 AUSTRALIA. Event. Impact. Earnings and target price revision. AUSTRALIA TLS AU Price (at 11:23, 21 Jul 2015 GMT) Neutral A$6.43 Valuation A$ 6.37 - DCF (WACC 6.8%, beta 0.8, ERP 5.0%, RFR 3.8%, TGR 1.2%) 12-month target A$ 6.30 12-month TSR % +3.3 Volatility Index

More information

LUCISANO MEDIA GROUP. New partner for Lucisano. Buy (maintained) Company Update

LUCISANO MEDIA GROUP. New partner for Lucisano. Buy (maintained) Company Update LUCISANO MEDIA GROUP Company Update Buy (maintained) 5:30PM MARKET PRICE: EUR2.82 TARGET PRICE: EUR3.40 (unchanged) Entertainment Data Shares Outstanding (m): 14.88 Market Cap. (EURm): 41.96 Enterprise

More information

Oz Minerals. Solid start to the year A$5.62 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation

Oz Minerals. Solid start to the year A$5.62 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation AUSTRALIA OZL AU Price (at 6:24, 21 Apr 216 GMT) Underperform A$5.62 Valuation A$ - DCF (WACC 1%, beta 1.4, ERP 5.%, RFR 3.8%) 4.61 12-month target A$ 4.6 12-month TSR % -15.5 Volatility Index High GICS

More information

WINDLAB LTD HOLD. Lakeland financial close delayed again. Downgrade to HOLD. COMPANY UPDATE EVENT IMPACT INVESTMENT VIEW

WINDLAB LTD HOLD. Lakeland financial close delayed again. Downgrade to HOLD. COMPANY UPDATE EVENT IMPACT INVESTMENT VIEW WINDLAB LTD HOLD Lakeland financial close delayed again. Downgrade to HOLD. Utilities / Renewable Electricity 7 November 2018 COMPANY UPDATE Ticker WND Stock Price $1.180 Target Price $1.350 Forecast Capital

More information

Ramsay Health Care. France begins to bite A$66.37 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst

Ramsay Health Care. France begins to bite A$66.37 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst AUSTRALIA RHC AU Price (at 06:11, 06 Aug 2015 GMT) Neutral A$66.37 Valuation A$ 64.54 - DCF (WACC 8.1%, beta 1.1, ERP 5.0%, RFR 3.8%, TGR 3.0%) 12-month target A$ 70.00 12-month TSR % +7.3 Volatility Index

More information

ONEVIEW HEALTHCARE PLC

ONEVIEW HEALTHCARE PLC ONEVIEW HEALTHCARE PLC BUY 2017 Result Green Shoots Emerging Health Care Equipment & Services / Health Care Technology 28 February 2018 COMPANY UPDATE Ticker ONE Stock Price $1.900 Target Price $3.04 Forecast

More information

Spotless Group Holdings

Spotless Group Holdings AUSTRALIA SPO AU Price (at 05:45, 31 Jan 2017 GMT) Neutral A$0.94 Valuation - Peer multiples A$ 1.02 12-month target A$ 1.02 12-month TSR % +18.3 Volatility Index High GICS sector Commercial & Professional

More information

QBE Insurance. QBE ANZ performance: LMI vs. Excl. LMI (A$m) Source: Company data, Macquarie Research, April 16. Earnings and target price revision

QBE Insurance. QBE ANZ performance: LMI vs. Excl. LMI (A$m) Source: Company data, Macquarie Research, April 16. Earnings and target price revision AUSTRALIA QBE AU Price (at 10:44, 27 Apr 2016 GMT) Neutral A$11.19 Valuation A$ - DCF (WACC 9.3%, beta 1.1, ERP 5.0%, RFR 3.8%) 11.34 12-month target A$ 12.00 12-month TSR % +12.7 Volatility Index Low/Medium

More information

Consolidated Operations Group (COG)

Consolidated Operations Group (COG) Consolidated Operations Group (COG) 10 April 2018 Outperform Upgrade to OUTPERFORM - Inflection point nearing $0.10 Jason Palmer jpalmer@taylorcollison.com.au +618 8217 3965 Summary (AUD) Market Capitalisation

More information

Oz Minerals. On track to meet guidance A$6.51 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation

Oz Minerals. On track to meet guidance A$6.51 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation AUSTRALIA OZL AU Price (at 08:20, 22 Jul 2016 GMT) Underperform A$6.51 Valuation A$ - DCF (WACC 9.0%, beta 1.4, ERP 5.0%, RFR 3.3%) 4.31 12-month target A$ 5.00 12-month TSR % -21.4 Volatility Index High

More information

Resetting expectations

Resetting expectations Company update 13 May 2016 TPI ENTERPRISES (TPE) Resetting expectations We retain a BUY rating with a revised 12-month price target of $3.21 p/sh. We assess market conditions to imply a more gradual ramp

More information

Automotive Holdings Group

Automotive Holdings Group AUSTRALIA AHG AU Price (at 06:14, 11 Aug 2016 GMT) Outperform A$4.61 Valuation - EV/EBITA A$ 4.09-4.63 12-month target A$ 4.36 12-month TSR % -0.2 Volatility Index Low GICS sector Retailing Market cap

More information

Regional Express Holdings Ltd REX

Regional Express Holdings Ltd REX 20 February 2006 REX $1.15 Analyst Ken Fleming (613) 6224 8511 ken.fleming@tricom.com.au Max Wheeler (613) 6224 9899 Fully diluted shares on issue 115.0M Market cap A$132.3M Performance & Valuation Last

More information

Downer EDI Two out of three ain t bad Event

Downer EDI Two out of three ain t bad Event AUSTRALIA DOW AU Price (at 06:26, 01 Dec 2016 GMT) Outperform A$6.08 Valuation - Sum of Parts A$ 5.69-6.38 12-month target A$ 6.40 12-month TSR % +9.6 Volatility Index Medium GICS sector Commercial & Professional

More information

Sims Metal Management

Sims Metal Management AUSTRALIA SGM AU Price (at 5:11, 17 Nov 215 GMT) Outperform A$7.19 Valuation - EV/EBIT A$ 8.49-9.6 12-month target A$ 8.9 12-month TSR % +26.6 Volatility Index Medium GICS sector Materials Market cap A$m

More information

Sandfire Resources. Swings to net cash A$5.34 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation

Sandfire Resources. Swings to net cash A$5.34 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation AUSTRALIA SFR AU Price (at 6:11, 7 Jul 216 GMT) Outperform A$5.34 Valuation A$ - DCF (WACC 9.%, beta 1.4, ERP 5.%, RFR 3.3%) 5.82 12-month target A$ 6.1 12-month TSR % +18.3 Volatility Index Medium GICS

More information

Kingsgate Consolidated

Kingsgate Consolidated AUSTRALIA KCN AU Price (at 6:11, 31 Jul 215 GMT) Underperform A$.67 Valuation A$ - DCF (WACC 12.%, beta 1.6, ERP 5.%, RFR 3.8%).3 12-month target A$.3 12-month TSR % -54.9 Volatility Index Very High GICS

More information

Challenger. Normalised margin trends expected to decline. Earnings and target price revision. Price catalyst. Action and recommendation

Challenger. Normalised margin trends expected to decline. Earnings and target price revision. Price catalyst. Action and recommendation 1H13E 2H13E 1H14E 2H14E 1H15E 2H15E AUSTRALIA CGF AU Price (at CLOSE#, 20 Aug 2012) Outperform A$3.76 Volatility index Low 12-month target A$ 4.57 12-month TSR % +26.4 Valuation - Sum of Parts A$ 4.57

More information

Noni B (NBL) SFH acquisition could be up to 60% EPS accretive. Key points. Risks and catalysts

Noni B (NBL) SFH acquisition could be up to 60% EPS accretive. Key points. Risks and catalysts Date Theme Company Update Company Noni B (NBL) SFH acquisition could be up to 6 EPS accretive Press reports today (Australian) suggest Noni B is a potential acquirer of Specialty Fashion Group (SFH), in

More information

SingTel. Earnings and target price revision. Price catalyst. Action and recommendation. Maintain Outperform.

SingTel. Earnings and target price revision. Price catalyst. Action and recommendation. Maintain Outperform. AUSTRALIA SGT AU Price (at 05:10, 06 Dec 2012 GMT) Outperform A$2.59 Volatility index Low 12-month target A$ 2.81 12-month TSR % +14.6 Valuation - Sum of Parts A$ 2.81 GICS sector Telecommunication Services

More information

PRICE $1.30 Regional Express Holdings Ltd REX

PRICE $1.30 Regional Express Holdings Ltd REX 16 November 2006 PRICE $1.30 Regional Express Holdings Ltd REX Analyst Ken Fleming (03) 6224 8511 ken.fleming@tricom.com.au Max Wheeler (03) 6224 9899 Fully diluted shares on issue 115M Market cap A$133M

More information

Origin Energy. 4Q Production. ORG reported its 4 th quarter production report, following on ConocoPhilips quarterly result.

Origin Energy. 4Q Production. ORG reported its 4 th quarter production report, following on ConocoPhilips quarterly result. AUSTRALIA ORG AU Price (at 06:11, 30 Jul 2015 GMT) Neutral A$11.35 Valuation A$ 12.79 - DCF (WACC 10.3%, beta 1.3, ERP 5.0%, RFR 3.8%, TGR 2.0%) 12-month target A$ 12.89 12-month TSR % +18.1 Volatility

More information

Noni B (NBL) BUY: FY18e EBITDA +12.8% Key points. Risks and catalysts

Noni B (NBL) BUY: FY18e EBITDA +12.8% Key points. Risks and catalysts Date 09 January 2018 Theme Company Update Company Noni B (NBL) BUY: FY18e EBITDA +12.8% NBL provided a positive 1H18 trading update today, advising LFL sales growth of 3.0% (1.5% in 1H17) and EBITDA of

More information

Fairfax / REA Group. No housing boom here. A$0.81 Valuation A$ Sum of Parts 12-month target A$ month TSR % +16.0

Fairfax / REA Group. No housing boom here. A$0.81 Valuation A$ Sum of Parts 12-month target A$ month TSR % +16.0 AUSTRALIA FXJ AU Price (at 05:11, 03 Nov 2016 GMT) Outperform A$0.81 Valuation A$ 0.88 - Sum of Parts 12-month target A$ 0.90 12-month TSR % +16.0 Volatility Index Low/Medium Market cap A$m 1,863 30-day

More information

Pilbara Minerals (PLS AU) Ramp-up gaining traction

Pilbara Minerals (PLS AU) Ramp-up gaining traction 17 January 219 Australia EQUITIES PLS AU Price (at 5:1, 16 Jan 219 GMT) Outperform A$.7 Valuation A$ 1.11 - DCF (WACC 1.%, beta 1.6, ERP 5.%, RFR 3.8%) 12-month target A$ 1.2 12-month TSR % +72.7 Volatility

More information

Earnings and target price revision. Price catalyst. Action and recommendation

Earnings and target price revision. Price catalyst. Action and recommendation AUSTRALIA TLS AU Price (at 13:07, 19 Apr 2012 GMT) Outperform A$3.39 Volatility index Low 12-month target A$ 3.55 12-month TSR % +13.0 Valuation A$ - DCF (WACC 9.6%, beta 0.9, ERP 6.0%, TGR 1.0%) 3.55

More information

Perseus Mining. Revised Sissingué plan A$0.31 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation

Perseus Mining. Revised Sissingué plan A$0.31 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation AUSTRALIA PRU AU Price (at 5:1, 31 Mar 217 GMT) Neutral A$.31 Valuation A$ - DCF (WACC 1.%, beta.4, ERP 5.%, RFR 3.3%).35 12-month target A$.32 12-month TSR % +3.2 Volatility Index Very High GICS sector

More information

Nuplex Industries. Should benefit from a weak Kiwi NZ$4.55 NEW ZEALAND. Event. Impact. Earnings and target price revision.

Nuplex Industries. Should benefit from a weak Kiwi NZ$4.55 NEW ZEALAND. Event. Impact. Earnings and target price revision. NEW ZEALAND NPX NZ Price (at 05:00, 31 Jul 2015 GMT) Outperform NZ$4.55 Valuation NZ$ 4.40 - DCF (WACC 12.5%, beta 1.4, ERP 7.0%, RFR 4.5%, TGR 2.0%) 12-month target NZ$ 4.75 12-month TSR % +10.6 Volatility

More information

MEDICAL DEVELOPMENTS INTERNATIONAL LTD

MEDICAL DEVELOPMENTS INTERNATIONAL LTD MEDICAL DEVELOPMENTS INTERNATIONAL LTD No pain in Germany HOLD Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals 6 April 2018 COMPANY UPDATE Ticker MVP Stock Price $7.10 Target Price $8.08

More information

Cochlear. Roberts replaced A$88.66 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation

Cochlear. Roberts replaced A$88.66 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation AUSTRALIA COH AU Price (at 06:47, 26 May 2015 GMT) Outperform A$88.66 Valuation A$ 81.19 - DCF (WACC 8.0%, beta 1.0, ERP 5.0%, RFR 3.8%, TGR 3.0%) 12-month target A$ 95.00 12-month TSR % +9.8 Volatility

More information

Noni B (NBL) BUY: Acquisition may signal the end of discounting in mature womenswear. Key points. Risks and catalysts

Noni B (NBL) BUY: Acquisition may signal the end of discounting in mature womenswear. Key points. Risks and catalysts Date Theme Company Update Company Noni B (NBL) BUY: Acquisition may signal the end of discounting in mature womenswear Noni B Group has agreed to acquire 5 brands from Specialty Fashion Group. Funded by

More information

Earnings and target price revision. Price catalyst. Catalyst: 1H14 result in February Action and recommendation

Earnings and target price revision. Price catalyst. Catalyst: 1H14 result in February Action and recommendation AUSTRALIA CBA AU Price (at 06:10, 10 Sep 2013 GMT) Neutral A$73.63 Valuation A$ - DCF (WACC 10.3%, beta 1.0, ERP 5.0%, RFR 5.5%) 50.40 12-month target A$ 66.15 12-month TSR % -5.0 Volatility Index Low

More information

Nanosonics Limited. Australia Health Care Equipment & Supplies. Growth outlook unchanged. Earnings Forecasts. Source Company, LINWAR Research

Nanosonics Limited. Australia Health Care Equipment & Supplies. Growth outlook unchanged. Earnings Forecasts. Source Company, LINWAR Research LINWAR Securities 30 August 2011 Nanosonics Limited Australia Health Care Equipment & Supplies Outperform (Unchanged) Price: Target Price: Stock's expected return (12mth) $0.57 $1.20 Capital growth 112.4%

More information

3P Learning. Coming to America... A$2.55 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation

3P Learning. Coming to America... A$2.55 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation AUSTRALIA 3PL AU Price (at 09:19, 02 Mar 2015 GMT) Outperform A$2.55 Valuation - DCF A$ 2.65-3.35 12-month target A$ 3.00 12-month TSR % +18.9 Volatility Index Low/Medium GICS sector Consumer Services

More information

Sirtex Medical. Healthy dose sales. Earnings and target price revision. Price catalyst. Catalyst: FY16 result on the 24th of August

Sirtex Medical. Healthy dose sales. Earnings and target price revision. Price catalyst. Catalyst: FY16 result on the 24th of August AUSTRALIA SRX AU Price (at CLOSE#, 11 Jul 2016) Outperform A$27.88 Valuation A$ 37.93 - DCF (WACC 9.0%, beta 1.2, ERP 5.0%, RFR 3.3%, TGR 1.5%) 12-month target A$ 38.00 12-month TSR % +37.4 Volatility

More information

Greencross. Check up. We review the outlook for GXL. Earnings and target price revision. Price catalyst. Catalyst: FY15/6 results

Greencross. Check up. We review the outlook for GXL. Earnings and target price revision. Price catalyst. Catalyst: FY15/6 results AUSTRALIA GXL AU Price (at 09:46, 13 Jul 2015 GMT) Outperform A$5.00 Valuation - EV/EBITA A$ 7.15-8.05 12-month target A$ 7.50 12-month TSR % +53.9 Volatility Index Medium GICS sector Health Care Equipment

More information

Filling in the gaps. Earnings and target price revision. Price catalyst. Action and recommendation

Filling in the gaps. Earnings and target price revision. Price catalyst. Action and recommendation AUSTRALIA PGH AU Price (at 06:11, 16 Jun 2015 GMT) Neutral A$4.45 Valuation - Peers' Multiples A$ 4.70 12-month target A$ 4.70 12-month TSR % +10.3 Volatility Index Low GICS sector Materials Market cap

More information

AUSTRALIA Price Event Valuation A$ month target A$ 5.20

AUSTRALIA Price Event Valuation A$ month target A$ 5.20 AUSTRALIA VOC AU Price (at 05:10, 22 Feb 2017 GMT) Outperform A$4.81 Valuation A$ 5.02 - DCF (WACC 7.7%, beta 1.2, ERP 5.0%, RFR 3.3%, TGR 1.0%) 12-month target A$ 5.20 12-month TSR % +12.2 Volatility

More information

Regis Resources. Strong 1H15 result A$1.29 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation

Regis Resources. Strong 1H15 result A$1.29 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation AUSTRALIA RRL AU Price (at 7:29, 13 2 GMT) Outperform A$1.29 Valuation A$ - DCF (WACC 9.%, beta 1.5, ERP 5.%, RFR 3.8%) 1.68 12-month target A$ 1.7 12-month TSR % +37.2 Volatility Index High GICS sector

More information

NEW ZEALAND Price Valuation NZ$ 1.74 Event 12-month target NZ$ month TSR % -10.1

NEW ZEALAND Price Valuation NZ$ 1.74 Event 12-month target NZ$ month TSR % -10.1 NEW ZEALAND GNE NZ Price (at 05:06, 24 Feb 2015 GMT) Underperform NZ$2.20 Valuation NZ$ 1.74 - DCF (WACC 8.1%, beta 0.6, ERP 7.0%, RFR 3.6%, TGR 2.1%) 12-month target NZ$ 1.82 12-month TSR % -10.1 Volatility

More information

Fisher & Paykel Healthcare

Fisher & Paykel Healthcare NEW ZEALAND FPH NZ Price (at 03:59, 16 Mar 2015 GMT) Outperform NZ$6.63 Valuation NZ$ 6.86 - DCF (WACC 8.8%, beta 0.9, ERP 7.0%, RFR 4.5%, TGR 2.0%) 12-month target NZ$ 7.25 12-month TSR % +11.6 Volatility

More information

Asset revaluation driven by almonds

Asset revaluation driven by almonds Company update 20 July 2015 RURAL FUNDS GROUP (RFF) Asset revaluation driven by almonds We retain a BUY rating with a 12-month target of $1.15 p/unit. RFF is a listed property trust with a portfolio of

More information

Generation Healthcare REIT

Generation Healthcare REIT AUSTRALIA GHC AU Price (at 06:13, 24 Aug 2015 GMT) Neutral A$1.65 Valuation - Sum of Parts A$ 1.51-1.59 12-month target A$ 1.59 12-month TSR % +1.8 Volatility Index Low GICS sector Real Estate Market cap

More information

Appen Limited (APX-AU) 29 August 2017

Appen Limited (APX-AU) 29 August 2017 Appen Limited (APX-AU) 29 August 2017 Pricing in another Upgrade Marketperform Adam Dellaverde adamd@taylorcollison.com.au +618 8217 3923 +6403 013 032 Summary Market capitalisation ($m) $438.7 Share price

More information

AtCor Medical Holdings Limited (ACG)

AtCor Medical Holdings Limited (ACG) Volume (million) AtCor Medical Holdings Limited (ACG) 30 March 2015 Speculative Buy Value Creation Ahead Post CPT1 Code Award $0.20 Marcus Hamilton mhamilton@taylorcollison.com.au +61 2 9210 1317 Summary

More information

Independence Group NL

Independence Group NL AUSTRALIA IGO AU Price (at 12:29, 26 Oct 216 GMT) Outperform A$4.25 Valuation A$ - DCF (WACC 8.4%, beta 1.2, ERP 5.%, RFR 3.3%) 3.98 12-month target A$ 5. 12-month TSR % +2.2 Volatility Index High GICS

More information

Fund Managers. Aust. Fund managers review & rank AUSTRALIA. Event. Stock Views

Fund Managers. Aust. Fund managers review & rank AUSTRALIA. Event. Stock Views AUSTRALIA 4 February 2016 Macquarie Securities (Australia) Limited Aust. Fund managers review & rank Event We review and rank the listed Australian under Macquarie Securities coverage, assessing fund performance,

More information

Meridian Energy. On tax depreciation NZ$2.08 NEW ZEALAND. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation

Meridian Energy. On tax depreciation NZ$2.08 NEW ZEALAND. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation NEW ZEALAND MEL NZ Price (at 05:00, 13 Jul 2015 GMT) Outperform NZ$2.08 Valuation NZ$ 2.50 - DCF (WACC 7.8%, beta 0.6, ERP 7.0%, RFR 3.6%, TGR 2.0%) 12-month target NZ$ 2.60 12-month TSR % +31.7 Volatility

More information

NIB Holdings. Lowest in 4 years still enough A$3.72 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst

NIB Holdings. Lowest in 4 years still enough A$3.72 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst AUSTRALIA NHF AU Price (at 09:52, 02 Mar 2016 GMT) Outperform A$3.72 Valuation A$ 3.85 - DCF (WACC 8.5%, beta 1.0, ERP 5.0%, RFR 3.8%, TGR 2.5%) 12-month target A$ 4.00 12-month TSR % +11.7 Volatility

More information

Aged Care. Propco sale & lease back A$2.71 A$5.75 A$6.15 AUSTRALIA. Event. Impact. Outlook

Aged Care. Propco sale & lease back A$2.71 A$5.75 A$6.15 AUSTRALIA. Event. Impact. Outlook AUSTRALIA JHC AU Price (at 06:10, 27 Apr 2015 GMT) Outperform A$2.71 Valuation A$ 2.97 - DCF (WACC 9.1%, beta 1.1, ERP 5.0%, RFR 4.5%, TGR 2.3%) 12-month target A$ 3.00 12-month TSR % +14.7 Volatility

More information

PanAust. Larger impairment and dividend cut A$1.35 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst

PanAust. Larger impairment and dividend cut A$1.35 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst AUSTRALIA PNA AU Price (at 7:6, 19 Feb 215 GMT) Outperform A$1.35 Valuation A$ - DCF (WACC 11.%, beta 1.7, ERP 5.%, RFR 3.8%) 1.73 12-month target A$ 1.7 12-month TSR % +25.9 Volatility Index High GICS

More information

CIMIC Group. Earnings and target price revision. No change. Price catalyst. Catalyst: Q1 earnings 13 April. Action and recommendation

CIMIC Group. Earnings and target price revision. No change. Price catalyst. Catalyst: Q1 earnings 13 April. Action and recommendation AUSTRALIA CIM AU Price (at 05:10, 31 Mar 2017 GMT) Outperform A$35.93 Valuation A$ 42.69 - DCF (WACC 8.5%, beta 1.4, ERP 5.0%, RFR 3.3%, TGR 2.0%) 12-month target A$ 42.50 12-month TSR % +22.0 Volatility

More information

2014 E 2015 E 2016 E 2017 E

2014 E 2015 E 2016 E 2017 E Equity Research 4 December 2014 Interpump Group Hydraulics M&A may power growth Rating BUY Target price EUR13 Interpump is up 25% since the beginning of the year, bolstered by strong interim results and

More information

Petro Rabigh Shutdown marred Q2 results

Petro Rabigh Shutdown marred Q2 results PETROR AB: Saudi Arabia US$5.07bn 17.4% US$11.19mn Market cap Free float Avg. daily volume RSI10 Vol th Target price n/a n/a Consensus price 32.18 48.3% over current Current price 21.70 as at 17/8/2011

More information

Family Zone Cyber Safety Limited (FZO) Company Update. Investment Summary. Investment Highlights. Investment Recommendation

Family Zone Cyber Safety Limited (FZO) Company Update. Investment Summary. Investment Highlights. Investment Recommendation BW EQUITIES RESEARCH 14 March 2017 Family Zone Cyber Safety Limited (FZO) Company Update BUY Rating: Target Price 1 : $0.46 Projected Return: 109% 1 12 month target Company Statistics Share Price (A$)

More information

Oz Minerals. Raises copper production outlook A$9.08 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst

Oz Minerals. Raises copper production outlook A$9.08 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst AUSTRALIA OZL AU Price (at 7:28, 3 Jan 27 GMT) Neutral A$9.8 Valuation A$ - DCF (WACC 9.%, beta.4, ERP 5.%, RFR 3.3%) 8.48 2-month target A$ 9.3 2-month TSR % +4.6 Volatility Index High GICS sector Materials

More information

Adacel Technologies (ADA)

Adacel Technologies (ADA) 9 November 2018 Chris Savage 612 8224 2835 Authorisation TS Lim 612 8224 2810 Adacel Technologies (ADA) Bad, but not that bad Recommendation Buy (unchanged) Price $0.88 Target (12 months) $1.50 (previously

More information

Fila Korea (081660) Widespread growth potential

Fila Korea (081660) Widespread growth potential Fila Korea (8166) BUY (Maintain), TP: W98, (Maintain) Stock price (Apr 26, KRW) 83,5 Yr to Sales OP EBT NP EPS % chg EBITDA P/E EV/EBITDA P/B ROE Market cap (USD mn) 697 Dec (W bn) (W bn) (W bn) (W bn)

More information

Whitehaven Coal. China outlook drives impairments A$1.04 AUSTRALIA. Event. Impact. Earnings and target price revision.

Whitehaven Coal. China outlook drives impairments A$1.04 AUSTRALIA. Event. Impact. Earnings and target price revision. AUSTRALIA WHC AU Price (at 06:10, 13 Aug 2015 GMT) Neutral A$1.04 Valuation A$ - DCF (WACC 8.0%, beta 1.6, ERP 5.0%, RFR 3.8%) 1.18 12-month target A$ 1.15 12-month TSR % +10.6 Volatility Index High GICS

More information

Multiplex Acumen Property Fund

Multiplex Acumen Property Fund ASX: MPF Bloomberg: MPF AU Reuters: MPF.AX 03 August 2006 $1.14 FY06 result: Continued delivery of unlisted property earnings growth # of Shares: 207M Market Cap: $230M Current Price: $1.14 % All Ords:

More information

Aventus Retail Property Fund

Aventus Retail Property Fund AUSTRALIA AVN AU Price (at 06:10, 29 Apr 2016 GMT) A$2.16 Volatility Index Low GICS sector Real Estate Market cap A$m 741 30-day avg turnover A$m 0.7 Number shares on issue m 343.2 Investment fundamentals

More information

Pharmaniaga MARKET PERFORM. 1Q15 Inline but Rich Valuations. Results Note. Price: RM6.91 Target Price: RM6.95. PP7004/02/2013(031762) Page 1 of 5

Pharmaniaga MARKET PERFORM. 1Q15 Inline but Rich Valuations. Results Note. Price: RM6.91 Target Price: RM6.95. PP7004/02/2013(031762) Page 1 of 5 Pharmaniaga 1Q15 Inline but Rich Valuations By the Kenanga Research Team l research@kenanga.com.my Period 1Q15 Actual vs. Expectations 1Q15 PATAMI of RM31.8m (+21% YoY) came in at 32% and 31% of our and

More information

Premier Investments. Making a move? A$14.18 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation

Premier Investments. Making a move? A$14.18 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation AUSTRALIA PMV AU Price (at 09:06, 29 Mar 2017 GMT) Outperform A$14.18 Valuation - Sum of Parts A$ 17.19 12-month target A$ 17.92 12-month TSR % +30.4 Volatility Index Low/Medium GICS sector Retailing Market

More information

National Australia Bank

National Australia Bank AUSTRALIA NAB AU Price (at 08:23, 03 Jul 2012 GMT) Outperform A$23.68 Volatility index Low 12-month target A$ 27.66 12-month TSR % +24.9 Valuation A$ - DCF (WACC 12.6%, beta 1.0, ERP 5.0%, RFR 5.8%) 25.14

More information

Generation Healthcare REIT All about spread Event

Generation Healthcare REIT All about spread Event AUSTRALIA GHC AU Price (at 04:51, 14 Feb 2015 GMT) Neutral A$1.60 Valuation - Sum of Parts A$ 1.18-1.26 12-month target A$ 1.59 12-month TSR % +5.1 Volatility Index Low GICS sector Real Estate Market cap

More information

COMPUMEDICS LTD HOLD. CMP Downgrades FY17 Guidance COMPANY UPDATE EVENT KEY TAKE-AWAYS INVESTMENT VIEW

COMPUMEDICS LTD HOLD. CMP Downgrades FY17 Guidance COMPANY UPDATE EVENT KEY TAKE-AWAYS INVESTMENT VIEW COMPUMEDICS LTD HOLD CMP Downgrades FY17 Guidance Health Care Equipment & Services / Health Care Equipment 7 July 2017 COMPANY UPDATE Ticker CMP Stock Price $0.560 Target Price $0.530 Forecast Capital

More information

Carsales.com. Motoring along nicely A$10.23 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation

Carsales.com. Motoring along nicely A$10.23 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation AUSTRALIA CRZ AU Price (at 9:48, 18 Feb 15 GMT) Outperform A$1.23 Valuation A$ 12.59 - DCF (WACC 8.1%, beta 1.2, ERP 5., RFR 3.8%, TGR 3.) 12-month target A$ 12.3 12-month TSR % +24.1 Volatility Index

More information

Automotive Holdings Group

Automotive Holdings Group AUSTRALIA AHE AU Price (at 03:28, 13 Feb 2015 GMT) Outperform A$3.82 Valuation - EV/EBITA A$ 3.85-4.34 12-month target A$ 4.34 12-month TSR % +19.6 Volatility Index Low/Medium GICS sector Retailing Market

More information

Axis REIT UNDERPERFORM. Splitting for Better Liquidity. Quick Bites. Price /Ex-Price: RM3.55/RM1.78 TP/Ex-Split: RM3.27/RM1.64

Axis REIT UNDERPERFORM. Splitting for Better Liquidity. Quick Bites. Price /Ex-Price: RM3.55/RM1.78 TP/Ex-Split: RM3.27/RM1.64 Axis REIT Splitting for Better Liquidity By Sarah Lim l sarahlim@kenanga.com.my News Proposed a 1:2 share split, essentially doubling its unit base from 547.8m to 1.1b units. Comments We were positively

More information

Nine Entertainment Co.

Nine Entertainment Co. AUSTRALIA NEC AU Price (at 06:47, 26 Feb 2015 GMT) Outperform A$2.03 Valuation A$ - DCF (WACC 8.2%, beta 1.2, ERP 5.0%, RFR 3.8%) 2.41 12-month target A$ 2.25 12-month TSR % +15.3 Volatility Index Low/Medium

More information

Newcrest Mining. Strong production result A$21.37 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst

Newcrest Mining. Strong production result A$21.37 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst AUSTRALIA NCM AU Price (at 5:37, 27 Oct 216 GMT) Neutral A$21.37 Valuation A$ - DCF (WACC 5.%, beta.8, ERP 5.%, RFR 3.3%) 15.8 12-month target A$ 24. 12-month TSR % +13.9 Volatility Index Medium GICS sector

More information

Korea Zinc (010130) Company Note. 1Q12 preview: Not over until it s over. BUY (Maintain)

Korea Zinc (010130) Company Note. 1Q12 preview: Not over until it s over. BUY (Maintain) Company Note April 1, 212 Korea Zinc (113) 12M rating BUY (Maintain) 12M TP W6, from W6, Up/downside +57% Stock Data KOSPI (Apr 9, pt) 1,997 Stock price (Apr 9, KRW) 381,5 Market cap (USD mn) 6,286 Shares

More information

Zain KSA bogged down by high debt

Zain KSA bogged down by high debt Vol th RSI10 Zain KSA ZAINKSA AB: Saudi Arabia US$2.464bn 48.3% US$16.50mn Market cap Free float Avg. daily volume Target price 7.30 12.31% over current Consensus price 7.62 17.2% over current Current

More information

SomnoMed (SOM) BUY: US channel conflicts abating in Q4. Key points. Risks and catalysts

SomnoMed (SOM) BUY: US channel conflicts abating in Q4. Key points. Risks and catalysts Date 27 April 2017 Theme Company Update Company SomnoMed (SOM) BUY: US channel conflicts abating in Q4 We maintain a BUY rating and 12-month price target of $4.50 per share. SomnoMed s Q3 update was a

More information

Yansab Better than expected results

Yansab Better than expected results YANSAB AB: Saudi Arabia US$6.91bn 39.8% US$23.37mn Market cap Free float Avg. daily volume RSI10 Vol th Target price n/a n/a Consensus price 56.00 21.5% over current Current price 46.10 as at 9/2/2011

More information

Sandfire Resources. Strong result but guidance light A$6.10 AUSTRALIA. Event. Impact. Earnings and target price revision.

Sandfire Resources. Strong result but guidance light A$6.10 AUSTRALIA. Event. Impact. Earnings and target price revision. AUSTRALIA SFR AU Price (at 06:37, 29 Jul 20 GMT) Outperform A$6.10 Valuation A$ - DCF (WACC 10.0%, beta 1.7, ERP 5.0%, RFR 3.8%) 8.02 12-month target A$ 8.00 12-month TSR % +35.8 Volatility Index Medium

More information

CSL: Global plasma report

CSL: Global plasma report AUSTRALIA AU Price (at 10:49, 11 Apr 2013 GMT) Outperform A$59.35 Volatility index Low 12-month target A$ 63.85 12-month TSR % +9.6 Valuation A$ 59.84 - DCF (WACC 8.5%, beta 0.9, ERP 5.0%, RFR 5.0%, TGR

More information

MNF Group Limited (MNF)

MNF Group Limited (MNF) MNF Group Limited (MNF) 16 February 2018 Outperform 1H18 Results: Excessive Sell-off Presents Buying Opportunity $5.14 Chris Reindler creindler@taylorcollison.com.au +61 2 9210 1335 Summary (AUD) Market

More information

Saudi Arabian Mining Co (Maaden AB Equity) Continuing steady performance

Saudi Arabian Mining Co (Maaden AB Equity) Continuing steady performance Vol mn RSI10 Saudi Arabian Mining Co- Mining Industrial MAADEN AB: Saudi Arabia 29 May 2018 US$17.47bn 35% US$6.79mn Market cap Free float Avg. daily volume Target price 47.60-15.5% over current Current

More information